CD34 and neuroblastoma: Using magnetic activated sorting of CD34+ PBPCs, which is the most widely used method for PBPC purging in high-risk neuroblastoma, tumor cell depletions rates ranging from 2 log to 4.6 log were reported in different studies for tumor cell lines and clinical samples, respectively [6, 29, 34–36].